Endothelial membrane potential regulates production of both nitric oxide and superoxide - A fundamental determinant of vascular health

Medical Hypotheses

Volumn 53, Issue 4, 1999, Pages 277-289

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; OXIDIZING AGENT; POTASSIUM CHANNEL; SUPEROXIDE;

ANIMAL CELL; CARDIOVASCULAR RISK; CATTLE; CELL CULTURE; CELL MEMBRANE POTENTIAL; CELL METABOLISM; CONDUCTANCE; HYPERPOLARIZATION; HYPERTENSION; INSULIN RESISTANCE; MEMBRANE CHANNEL; NONHUMAN; OXIDATION; POLARIZATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SODIUM INTAKE; THROMBOSIS; THYROID FUNCTION; VASCULAR ENDOTHELIUM;

ANIMALIA; BOS TAURUS;

EID: 0032709605     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0758     Document Type: Article

References (206)

1. Lückhoff A., Busse R. Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflügers Arch. 416:1990;305-311.
2. Busse R., Fleming I., Hecker M. Signal transduction in endothelium-dependent vasodilatation. Eur Heart J. 14:1993;2-9.
3. Himmel H. M., Whorton A. R., Strauss H. C. Intracellular calcium currents, and stimulus-response coupling in endothelial cells. Hypertension. 21:1993;112-127.
4. Nilius B., Riemann D. Ion channels in human endothelial cells. Gen Physiol Biophys. 9:1990;89-112.
5. Busse R., Mülsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett. 265:1990;133-136.
6. Knowles R. G., Moncada S. Nitric oxide synthases in mammals. Biochem J. 298:1994;249-258.
7. Lin L. L., Wartmann M., Lin A. Y. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 72:1993;269-278.
8. Hecker M., Bara A. T., Bauersachs J., Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 481:1994;407-414.
9. McCabe R. D., Bakarich M. A., Srivastava K., Young D. B. Potassium inhibits free radical formation. Hypertension. 24:1994;77-82.
10. Haddy F. J. Minireview. Potassium and blood vessels. Life Sci. 16:1975;1489-1498.
11. +-induced membrane depolarization. J Cell Physiol. 166:1996;274-280.
12. Woolfson R. G., Poston L. Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension. 17:1991;619-625.
13. Mohazzab-H K. M., Kaminski P. M., Wolin M. S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol. 266:1994;H2568-H2572.
14. Moncada S., Palmer R. M. J., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 43:1991;109-142.
15. Furlong B., Henderson A. H., Lewis M. J., Smith J. A. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Brit J Pharmacol. 90:1987;687-692.
16. Radomski M. W., Palmer R. M. J., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1987;1057-1058.
17. Kubes P., Suzuki M., Granger D. N. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci. 88:1991;4651-4655.
18. Bath P. M. W., MacGregor G. A. Spontaneous nitric oxide donors inhibit monocyte chemotaxis and increase intracellular cGMP concentration. J Vasc Res. 29:1992;81.
19. Moilanen E., Vuorinen P., Kankaareranta H. NO donors inhibit human neutrophil activation in vivo. J Vasc Res. 29:1992;170.
20. Ma X. L., Weyrich A. S., Lefer D. J., Lefer A. M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res. 72:1993;403-412.
21. Lincoln T. M. Cyclic GMP and mechanisms of vasodilation. Pharm Ther. 41:1989;479-502.
22. iand uncoupling stress from myosin phosphorylation. Am J Physiol. 263:1992;C461-C467.
23. Cooke J. P., Tsao P. S. Is NO an endogenous antiatherogenic molecule. Arterioscler Thromb. 14:1994;653-655.
24. Clementi E., Sciorati C., Riccio M. Nitric oxide action on growth factor-elicited signals. J Biol Chem. 270:1995;22277-22282.
25. Lloyd-Jones D. M., Bloch K. D. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 47:1996;365-375.
26. Sarkar R., Meinberg E. G., Stanley J. C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 78:1996;225-230.
27. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle. Circulation. 95:1997;1101-1103.
28. Boulanger C., Lüscher T. F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 85:1990;587-590.
29. Kuchan M. J., Frangos J. A. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol. 264:1993;H150-H156.
30. Heller R., Bussolino F., Ghigo D. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharm. 44:1992;223-229.
31. Lang D., Lewis M. J. Inhibition of inositol 1,4,5-triphosphate formation by cyclic GMP in cultured aortic endothelial cells of the pig. Brit J Pharmacol. 102:1991;277-281.
32. Beckman J. S., Beckman T. W., Chen J. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci. 87:1990;1620-1624.
33. White C. R., Brock T. A., Chang L. Y. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci. 91:1994;1044-1048.
34. Mügge A., Elwell J. H., Peterson T. E., Harrison D. G. Release of intact endothlium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol. 260:1991;C219-C225.
35. Nakazono K., Watanabe N., Matsuno K. Does superoxide underlie the pathogenesis of hypertension. Proc Natl Acad Sci. 88:1991;10045-10048.
36. Hattori Y., Kawasaki H., Abe K., Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetric rat aorta. Am J Physiol. 261:1991;H1086-H1094.
37. Ting H. H., Timimi F. K., Boles K. S. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 97:1996;22-28.
38. Heitzer T., Just H., Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 94:1996;6-9.
39. Levine G. N., Frei B., Koulouris S. N. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
40. Laursen J. B., Rajagopalan S., Galis Z. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 95:1997;588-593.
41. Steinberg D., Parthasarathy S., Carew T. E. Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 320:1989;915-924.
42. Steinbrecher U. P., Parthasarathy S., Leake D. S. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci. 81:1984;3883-3887.
43. Warso M. A., Lands W. E. M. Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology. Brit Med Bull. 33:1983;75-00.
44. Hampel G., Watanabe K., Weksler B. B., Jaffe E. A. Selenium deficiency inhibits prostacyclin release and enhances production of platelet activating factor by human endothelial cells. Biochim Biophys Acta. 1006:1989;151-158.
45. Rossi M. A., Fidale F., Garramone A. Effect of 4-hydroxyalkenals on hepatic phosphatidylinositol-4,5-bisphosphate-phospholipase C. Biochem Pharm. 39:1990;1715-1719.
46. Natarajan V., Scribner W. M., Taher M. M. 4-hydroxynonenal, a metabolite of lipid peroxidation, activates phospholipase D in vascular endothelial cells. Free Rad Biol Med. 15:1993;365-375.
47. Natarajan V., Taher M. M., Roehm B. Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty acid hydroperoxide. J Biol Chem. 268:1993;930-937.
48. Shasby D. M., Yorek M., Shasby S. S. Exogenous oxidants initiate hydrolysis of endothelial cell inositol phospholipids. Blood. 72:1988;491-499.
49. Weinheimer G., Wagner B., Osswald H. Interference of phorbolesters with endothelium-dependent vascular smooth muscle relaxation. Eur J Pharmacol. 130:1986;319-322.
50. Lewis M. J., Henderson A. H. A phorbol ester inhibits the release of endothelium-derived relaxing factor. Eur J Pharmacol. 137:1987;167-171.
51. Davda R. K., Chandler L. J., Guzman N. J. Protein kinase C modulates receptor-independent activation of endothelial nitric oxide synthase. Eur J Pharmacol-Mol Pharmacol Sect. 266:1994;237-244.
52. Ohara Y., Sayegh H. S., Yamin J. J., Harrison D. G. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertension. 25:1995;415-420.
53. Matsubara T., Ziff M. Superoxide anion release by human endothelial cells: Synergism between a phorbol ester and a calcium ionophore. J Cell Physiol. 127:1986;207-210.
54. Murphy H. S., Shayman J. A., Till G. O. Superoxide responses of endothelial cells to C5a and TNF-α: divergent signal transduction pathways. Am J Physiol. 263:1992;L51-L59.
55. Hattori Y., Kasai K., Banba N. Effect of a phorbol ester on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Endocrinol Japon. 39:1992;341-345.
56. Hsieh H. J., Li N. Q., Frangos J. A. Shear-induced platelet-derived growth factor gene expression in human endothelial cells is mediated by protein kinase C. J Cell Physiol. 150:1992;552-558.
57. Numaguchi K., Shimokawa H., Nakaike R. PKC inhibitors prevent endothelial dysfunction after myocardial ischemia-reperfusion in rats. Am J Physiol. 270:1996;H1634-H1639.
58. Chen C. C., Rosenbloom C. L., Anderson D. C., Manning A. M. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IκB-α phosphorylation. J Immunol. 155:1995;3538-3545.
59. Collins T. Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest. 68:1993;499-508.
60. Renier G., Skamene E., DeSanctis J., Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Arterioscler Thromb. 13:1993;1515-1524.
61. Yoshizumi M., Perrella M. A., Burnett J. C. Jr, Lee M.-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 73:1993;205-209.
62. Kobayashi M., Shimada K., Ozawa T. Human recombinant interleukin-1β- and tumor necrosis factor α-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol. 144:1990;383-390.
63. Anderson M. T., Staal F. J. T., Gitler C. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc Natl Acad Sci. 91:1994;11527-11531.
64. 2and vanadate in vitro. Biochem Biophys Res Comm. 188:1992;773-779.
65. 2on protein tyrosine phosphatase activity in HER14 cells. Free Rad Biol Med. 16:1994;399-403.
66. Schenk H., Klein M., Erdbrügger W. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc Natl Acad Sci. 91:1994;1672-1676.
67. Tannen R. L. Effects of potassium on blood pressure control. Ann Int Med. 98:1983;773-780.
68. Cappuccio F. P., MacGregor G. A. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens. 9:1991;465-473.
69. Karppanen H. An antihypertensive salt: crucial role of Mildred Seelig in its development. J Am Coll Nutr. 13:1994;493-495.
70. Tobian L. High-potassium diets markedly protect against stroke deaths and kidney disease in hypertensive rats, an echo from prehistoric days. J Hypertens. 4:1986;S67-S76.
71. Khaw K.-T., Barrett-Connor E. Dietary potassium and stroke-associated mortality. N Engl J Med. 316:1987;235-240.
72. Tobian L., Jahner T. M., Johnson M. A. High K diets markedly reduce athero-sclerotic cholesterol ester deposition in aortas of rats with hypercholesterolemia and hypertension. Am J Hypertens. 3:1990;133-135.
73. Sugimoto T., Tobian L., Ganguli M. C. High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. Hypertension. 11:1988;579-585.
74. Raij L., Lüscher T. F., Vanhoutte P. M. High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension. 12:1988;562-567.
75. Sudhir K., Kurtz T. W., Yock P. G. Potassium preserves endothelial function and enhances aortic compliance in Dahl rats. Hypertension. 22:1993;315-322.
76. Taddei S., Mattei P., Virdis A. Effect of potassium on vasodilation to acetyl-choline in essential hypertension. Hypertension. 23:1994;485-490.
77. +-ATPase: mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol. 269:1995;C295-C311.
78. Moore R. D. Effects of insulin upon ion transport. Biochim Biophys Acta. 737:1983;1-49.
79. Erlij D., Grinstein S. The number of sodium ion pumping sites in skeletal muscle and its modi?cation by insulin. J Physiol Lond. 259:1976;13-31.
80. +-dependent ATPase molecules from intracellular stores to the plasma membrane in frog skeletal muscle. Biochem J. 272:1990;727-733.
81. +-ATPase from intracellular compartments to the plasma membrane in mammalian skeletal muscle. J Biol Chem. 267:1992;5040-5043.
82. 2-subunit in the surface of rat skeletal muscle: morphological evidence. Am J Physiol. 265:1993;C1716-C1722.
83. Marette A., Burdette E., Douen A. Insulin induces the translocation of GLUT-4 glucose transporters from a unique intracellular organelle to transverse tubules in rat skeletal muscle. Diabetes. 41:1992;1562-1569.
84. Baron A. D. Hemodynamic actions of insulin. Am J Physiol. 267:1994;E187-E202.
85. Baron A. D., Steinberg H. O., Chaker H. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 96:1995;786-792.
86. 2+-ATPase. Am J Hypertens. 5:1992;637-641.
87. Kahn A. M., Ayyar M., Allen J. C. Physiological insulin concentrations inhibit agonist-stimulated contraction of cultured canine femoral artery vascular smooth muscle cells (VSMC). FASEB J. 6:1992;A1543.
88. Steinberg H. O., Brechtel G., Johnson A. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 94:1994;1172-1179.
89. Scherrer U., Randin D., Vollenweider P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 94:1994;2511-2515.
90. Moreau P., Yamaguchi N., de Champlain J. Increased activity in the nitric oxide pathway during chronic euglycemic hypertension in the rat. J Hypertens. 11:1993;S270-S271.
91. Tack C. J. J., Lutterman J. A., Vervoort G. Activation of the sodium-potassium pump contributes to insulin-induced vasodilation in humans. Hypertension. 28:1996;426-432.
92. Laakso M., Edelman S. V., Brechtel G., Baron A. D. Decreased effect of insulin to stimulate skeletal muscle blood ?ow in obese man. J Chin Invest. 85:1990;1844-1852.
93. Feldman R. D., Bierbrier G. S. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet. 342:1993;707-709.
94. Vollenweider P., Randin D., Tappy L. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest. 93:1994;2365-2371.
95. Baron A. D. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes. 45:1996;S105-S109.
96. Baron A. D., Brechtel-Hook G., Johnson A. D., Hardin D. Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension. 21:1993;129-135.
97. Laakso M., Edelman S. V., Brechtel G., Baron A. D. Impaired insulin-mediated skeletal muscle blood ?ow in patients with NIDDM. Diabetes. 41:1992;1076-1083.
98. Lüscher T. F., Vanhoutte P. M., Boulanger C. Endothelial dysfunction in hypertension. Rubanyi G. M. Cardiovascular Significance of Endothelium-Derived Vasoactive Factors. 1991;199-221 Futura Publishing Co., Inc. Mount Kisco, NY.
99. Petrie J. R., Ueda S., Webb D. J. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation. 93:1996;1331-1333.
100. Reaven G. M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
101. Nolan J. J., Ludvik B., Beerdsen P. Improvement in glucose toelrance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1994;1188-1193.
102. Iwamoto Y., Kosaka K., Kuzuya T. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 19:1996;151-156.
103. Kumar S., Boulton A. J. M., Beck-Nielsen H. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:1996;701-709.
104. Anderson R. A., Cheng N., Bryden N. Beneficial effects of chromium for people with type II diabetes. Diabetes. 45:1996;124A.
105. Jovanovic-Peterson L., Gutierrez M., Peterson C. M. Chromium supplementation for gestational diabetic women (GDM) improves glucose tolerance and decreases hyperinsulinemia. Diabetes. 45:1996;337A.
106. Cefalu W. T., Bell-Farrow A. D., Wang Z. Q. The effect of chromium supplementation on carbohydrate metabolism and body fat distribution. Diabetes. 46:1997;55A.
107. Lin M. H., Akera T. Increased (Na,K)-ATPase concentrations in various tissues of rats caused by thyroid hormone treatment. J Biol Chem. 253:1978;723-726.
108. Ismail-Beigi F. Thyroid hormone regulation of Na, K-ATPase expression. Trends Endocrinol Metab. 4:1993;152-155.
109. Ismail-Beigi F., Edelman I. S. Mechanism of thyroid calorigenesis: role of active sodium transport. Proc Natl Acad Sci. 67:1970;1071-1078.
110. Attarian E. Myxedema and hypertension. NY JMed. 63:1963;2801-2804.
111. Klein I., Ojamaa K. Thyroid hormone and blood pressure regulation. Laragh J H., Brenner B. M. Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. 1995;2247-2262 Raven Press, New York.
112. Rosenqvist U., Borens L. O. Enhancement of the alpha adrenergic response in aorta from hypothyroid rabbits. Life Sci. 11:1972;595-604.
113. Fuller H. Jr, Spittell J. A., McConehey W. M., Schirger A. Myxedema and hypertension. Postgrad Med. 40:1966;425-428.
114. Bing R. F., Briggs R. S. J., Burden A. C. Reversible hypertension and hypothyroidism. Clin Endocrinol. 13:1980;339-342.
115. Klein I. Thyroid hormone and the cardiovascular system. Am J Med. 88:1990;631-637.
116. Williams L. T., Lefkowitz R. J., Watanabe A. M. Thyroid hormone regulation of β-adrenergic receptor number. J Biol Chem. 252:1977;2787-2789.
117. Van Inwegen R. G., Robinson R. A., Thompson W. J. Cyclic neucleotide phosphodiesterase and thyroid hormones. J Biol Chem. 250:1975;2452-2456.
118. Menof P. Essential hypertension: its control by a new method. A preliminary report. S Afr Med J. 24:1950;172-180.
119. Menof P. High blood pressure and thyroid insuf?ciency - recent developments. S Afr Med J. 41:1967;506-508.
120. Barnes B. O. Hypertension and the thyroid gland. Clin Exp Pharm Physiol. Suppl 2:1975;167-170.
121. Starr P. Atherosclerosis, hypothyroidism, and thyroid hormone therapy. Adv Lipid Res. 16:1978;345-371.
122. Barnes B. O. Prophylaxis of ischaemic heart-disease by thyroid therapy. Lancet. ii:1959;149-152.
123. Israel M. Long term thyroid-vitamin treatment of atherosclerosis in chronic diseases. Southwestern Med. 44:1963;15-25.
124. Wren J. C. Symptomatic atherosclerosis: prevention or modi?cation by treatment with dessicated thyroid. J Am Ger Soc. 19:1971;7-22.
125. Barnes B. O., Barnes C. W. Heart Attack Rareness in Thyroid-Treated Patients. 1972;Charles C Thomas, Springfield, I. L.
126. Vargas F., Fernández-Rivas A., Estañ J. G., Garcia del Rio C. Endothelium-dependent and endothelium-independent vasodilation in hyperthyroid and hypothyroid rats. Pharmacology. 51:1995;308-314.
127. Shahedi M., Laborde K., Bussiéres L., Sachs C. Acute and early effects of aldosterone on Na-K-ATPase activity in Madin-Darby canine kidney epithelial cells. Am J Physiol. 264:1993;F1021-F1026.
128. Horisberger J., Rossier B. C. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension. 19:1992;221-227.
129. Dahl L. K. Salt and hypertension. Am J Clin Nutr. 25:1972;231-244.
130. Meneeley G. R., Battarbee H. H. The high sodium-low potassium environment and hypertension. Am J Cardiol. 38:1976;768-786.
131. Stamler J., Rose G., Elliott P. Findings of the international cooperative INTERSALT study. Hypertension. 17:1991;I-9-I-15.
132. Oliver W. J., Cohen E. L., Neel J. V. Blood pressure, sodium intake, and sodium-related hormones in the Yanomamo Indians, a 'no-salt' culture. Circulation. 52:1975;146-151.
133. Crofton J. T., Share L., Shade R. E. The importance of vasopressin in the development and maintenance of DOCA-salt hypertension in the rat. Hypertension. 1:1979;31-38.
134. +) ATPase associated with essential hypertension. Nature. 300:1982;650-652.
135. Moreth K., Renner D., Schoner W. A quantitative receptor assay for 'digitalislike' compounds in serum. Demonstration of raised concentrations in essential hypertension and correlation with arterial blood pressure. Klin Wochenschr. 65:1987;179-184.
136. Takahashi H., Matsusawa M., Okabayashi H. Endogenous digitalislike substance in an adult population in Japan. Am J Hypertens. 1:1988;168S-172S.
137. Hamlyn J. M., Blaustein M. P., Bova S. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci. 88:1991;6259-6263.
138. Fischer P. W. F., Giroux A. Effects of dietary magnesium on sodium-potassium pump action in the heart of rats. J Nutr. 117:1987;2091-2095.
139. Altura B. T., Altura B. M. Endothelium-dependent relaxation in coronary arteries requires magnesium ions. Brit J Pharmacol. 91:1987;449-451.
140. Dyckner T., Wester P. O. Effect of magnesium on blood pressure. Brit Med J. 286:1983;1847-1849.
141. Motoyama T., Sano H., Fukuzaki H. Oral magnesium supplementation in patients with essential hypertension. Hypertension. 13:1989;227-232.
142. Gold M. E., Buga G. M., Byrns R. E. Extracellular magnesium (Mg) depletion enhances vascular EDRF and endothelium (E)-dependent cyclic GMP formation, whereas Mg repletion causes E- and cyclic GMP-independent relaxation. FASEB J. 2:1988;A710.
143. Cooke J. P., Rossitch E. Jr, Andon N. A. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 88:1991;1663-1671.
144. Wellman G C., Bevan J. A. Barium inhibits the endothelium-dependent component of ?ow but not acethylcholine-induced relaxation in isolated rabbit cerebral arteries. J Pharmacol Exp Ther. 274:1995;47-53.
145. Sauve R., Chahine M., Tremblay J., Hamet P. Single-channel analysis of the electrical response of bovine aortic endothelial cells to bradykinin stimulation: contribution of a Ca2(+)-dependent K+ channel. J Hypertens. 8:1990;S193-S201.
146. Groschner K., Graier W. F., Kukovetz W. R. Activation of a small-conductance Ca (2+)-dependent K+ channel contributes to bradykinin-induced stimulation of nitric oxide synthesis in pig aortic endothelial cells. Biochim Biophys Acta. 1137:1992;162-170.
147. Busse R., Fichtner H., Lückhoff A., Kohlhardt M. Hyperpolarization and increased free calcium in acetylcholine-stimulated endothelial cells. Am J Physiol. 255:1988;H965-H969.
148. +channel in cultured vascular endothelial cells. Pflügers Arch. 422:1992;66-74.
149. Dietze G. J., Wicklmayr M., Rett K. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes. 45:1996;S110-S114.
150. Erdös E. G. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol. 15:1990;S20-S24.
151. Wiemer G., Schölkens B. A., Becker R. H. A., Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 18:1991;558-563.
152. Busse R., Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Arch Pharmacol. 344:1991;126-129.
153. Mombouli J.-V., Nephtali M., Vanhoutte P. M. Effects of the converting enzyme inhibitor cilazaprilat on endothelium-dependent responses. Hypertension. 18:1991;II-22-II-29.
154. Griendling K. K., Minieri C. A., Ollerenshaw J. D., Alexander R. W. Angiotension II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 74:1994;1141-1148.
155. Rajagopalan S., Kurz S., Münzel T. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 97:1996;1916-1923.
156. 2+entry into endothelial cells by activation of potassium channels and membrane hyperpolarization. Biochem J. 291:1993;263-267.
157. +-ATPase activity may aid the prevention and treatment of essential hypertension. Med Hypoth. 13:1984;451-463.
158. Blaustein M. P. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol. 232:1977;C165-C000.
159. Inoguchi T., Battan R., Handler E. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci. 89:1992;11059-11063.
160. Inoguchi T., Xia P., Kunisaki M. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol. 267:1994;E369-E379.
161. Ishii H., Hirousek M. R., Koya D. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science. 272:1996;728-731.
162. Steinberg H., Leaming R., Cronin J. Elevated free fatty acids (FFA) levels impair endothelium dependent vasodilation. Diabetes. 45:1996;11A.
163. Carper J. Miracle Cures. 1997;HarperCollins, New York. p. 269-270.
164. Kunisaki M., Bursell S.-E., Clermont A. C. Vitamin E prevents diabetes-induced abnormal retinal blood ?ow via the diacylglycerol-protein kinase C pathway. Am J Physiol. 269:1995;E239-E246.
165. Kunisaki M., Bursell S.-E., Umeda F. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes. 43:1994;1372-1377.
166. Lee I.-K., Koya D., Ishii H., King G. L. Vitamin E (vit E) prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes. 45:1996;64A.
167. Koya D., Lee I.-K., Ishii H., Bursell S. E. Vitamin E normalized glomerular hyper?ltration and protein kinase C activation by increasing diacylglycerol kinase in diabetic rats. Diabetes. 45:1996;205A.
168. Shimokawa H., Lam J. Y. T., Chesbro J. H. Effects of dietary supplementation with cod-liver oil on endothelium-dependent responses in porcine coronary arteries. Circulation. 76:1987;898-905.
169. Boulanger C., Schini V. B., Hendrickson H., Vanhoutte P. M. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Brit J Pharmacol. 99:1990;176-180.
170. McVeigh G. E., Brennan G. M., Johnston G. D. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 36:1993;33-38.
171. Marsh J. B., Topping D. L., Nestel P. J. Comparative effects of dietary ?sh oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rate. Biochim Biophys Acta. 922:1987;239-243.
172. Wong S.-H., Marsh J. B. Inhibition of apolipoprotein secretion and phosphatidate phosphohydrolase activity by eicosapentaenoic and docosahexaenoic acids in the perfused rat liver. Metabolism. 37:1988;1177-1181.
173. Surette M. E., Whelan J., Broughton K. S., Kinsella J. E. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta. 1126:1992;199-205.
174. Lee T. H., Hoover R. L., Williams J. D. Effect of dietary enrichment with eicosa-pentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 312:1985;1217-1224.
175. Kugiyama K., Kerns S. A., Morrisett J. D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modi?ed low-density in modified low-density lipoproteins. Nature. 344:1990;160-162.
176. Sugiyama S., Kugiyama K., Ohgushi M. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ Res. 74:1994;565-575.
177. Kugiyama K., Ohgushi M., Sugiyama S. Lysophophatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res. 71:1992;1422-1428.
178. Creager M. A., Cooke J. P., Mendelsohn M. E. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 86:1990;228-234.
179. Sorensen K. E., Celermajer D. S., Georgakopoulous G. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 93:1994;50-55.
180. Wascher T. C., Posch K., Wallner S. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase. Biochem Biophys Res Comm. 234:1997;35-38.
181. Böger R. H., Bode-Böger S. M., Mügge A. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NOproduction. Atherosclerosis. 117:1995;273-284.
182. Creager M. A., Gallagher S. H., Girerd X. J. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
183. Nakanishi K., Vinten-Johansen J., Lefer D. J. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol. 263:1992;H1650-H1658.
184. Pieper G. M., Peltier B. A. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol. 25:1995;397-403.
185. Clarkson P., Adams M. R., Powe A. J. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 97:1996;1989-1994.
186. Zhao B., Li X., He R. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophysics. 14:1989;175-185.
187. Sato Y., Nakatsuka H., Watanabe T. Possible contribution of green tea drinking habits to the prevention of stroke. Tohoku J Exp Med. 157:1989;337-343.
188. Nagamatsu M., Nickander K. K., Schmelzer J. D. Lipoic acid improves nerve bood ?ow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1995;1160-1167.
189. Sachse G., Willms B. Efficacy of thiotic acid in the therapy of peripheral diabetic neuropathy. Horm Metab Res. 9:1980;105-107.
190. Ziegler D., Hanefeld M., Ruhnau K. J. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. Diabetologia. 38:1995;1425-1433.
191. Packer L., Witt E. H., Tritschler H. J. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med. 19:1995;227-250.
192. Handelman G. J., Han D., Tritschler H., Packer L. α-lipoic acid reduction by mammalian cells to the dithiol form and release into the culture medium. Biochem Pharm. 47:1994;1725-1730.
193. Pick U., Haramaki N., Constantinescu A. Glutathione reductase and lipoamide dehydrogenase have opposite sterospecificities for a-lipoic acid enantiomers. Biochem Biophys Res Comm. 206:1995;724-730.
194. Arner E. S., Nordberg J., Holmgren A. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Comm. 225:1996;268-274.
195. Spector A., Huang R.-R. C., Yan G.-Z., Wang R.-R. Thioredoxin fragment 31-36 is reduced by dihydrolipoamide and reduces oxidized protein. Biochem Biophys Res Comm. 150:1988;156-162.
196. Patel J. M., Block E. R. Sulfhydryl-disulfide modulation and the role of disul?de oxidoreductases in regulation of the catalytic activity of nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol. 13:1995;352-359.
197. Patel J. M., Zhang J., Block E. R. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: role of thioredoxin in regulation of catalytic activity. Am J Respir Cell Mol Biol. 15:1996;410-419.
198. 10. Res Comm Chem Pathol Pharmacol. 31:1981;129-140.
199. Digiesi V., Cantani F., Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res. 47:1990;841-845.
200. Digiesi V., Cantini F., Oradei A. Coenzyme Q10 in essential hypertension. Mol Aspects Med. 15:1994;S257-S263.
201. 10. Mol Aspects Med. 15:1994;S265-S272.
202. Beyer R. E. The participation of coenzyme Q in free radical production and antioxidation. Free Rad Biol Med. 8:1990;545-565.
203. Stoyanovsky D. A., Osipov A. N., Quinn P. J., Kagan V. E. Ubiquinone-dependent recycling of vitamin E radicals by superoxide. Arch Biochem Biophys. 323:1995;343-351.
204. McCarty, M. F. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation, 1997.
205. Mukai K., Kikuchi S., Urano S. Stopped-?ow kinetic study of the regeneration reaction of tocopheroxyl radical by reduced ubiquinone-10 in solution. Biochim Biophys Acta. 1035:1990;77-82.
206. Stocker R., Bowry V. M., Frei B. Ubiquinol-10 protects human low density lipoprotein more effi ciently against lipid peroxidation than does α-tocopherol. Proc Natl Acad Sci. 88:1991;1646-1650.